News And Announcements
Santhera enters agreement with Polyphor to licence POL6014
Santhera Pharmaceuticals announced on Thursday that it has entered into a license agreement with Polyphor for POL6014, a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases such as non-cystic fibrosis bronchiectasis (NCFB), alpha-1 antitrypsin deficiency (AATD) and primary ciliary dyskinesia (PCD).
ConvaTec results hit by supply problems; sees tough 2018 H1
Medical equipment maker ConvaTec on Thursday said its 2018 first half would be hit by the problems that led to a profits warning last year, as supply issues continued to weigh on the catheter and colostomy bag maker.
Lancashire Holdings swing to loss as catastrophes take their toll
FTSE 250 insurer Lancashire Holdings said on Thursday that it swung to a full-year loss as it took a hit from natural catastrophes.
GKN makes latest play in Melrose takeover ping-pong
GKN made efforts to return the ball back over the net on Thursday, as its ping-pong match with Melrose over the latter’s takeover proposals continued.
AVEVA's merger target at Schneider sees some good growth
Engineering data and design IT systems provider AVEVA Group noted the announcement on Thursday of the Schneider Electric financial results for the calendar year 2017, which included commentary on the performance of its industrial software portfolio.
RELX hikes final dividend, proposes merger of UK and Dutch parents
RELX Group, the information and analytics formerly known as Reed Elsevier, lifted its final dividend 10%, pledged to repeat its £700m share buyback in 2018 and proposed to merge its UK and Dutch parent companies in a further simplification of its corporate structure.
AstraZeneca's selumetinib gets FDA designation for new treatment
AstraZeneca, along with Merck & Co, announced on Thursday that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).